PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months

Authors :: Shrushma Loi
Andrew M Wardley
David Miles
A-L Vallier
Janet A. Dunn
Helena M. Earl
Louise Hiller
Emma Ogburn
Helen B Higgins
David Cameron
Source :: Journal of Clinical Oncology. 32:TPS656-TPS656
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: TPS656 Background: PERSEPHONE is a randomised controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer. Methods: 4,000 patie...

Subjects :: Cancer Research
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
law.invention
Surgery
Oncology
Randomized controlled trial
law
Trastuzumab
Internal medicine
medicine
In patient
skin and connective tissue diseases
business
neoplasms
medicine.drug
Early breast cancer

Tools